This meta-analysis of 3 randomized clinical trials evaluates the association of combined anti–PD-L1 agents with survival and response rate among patients with metastatic renal cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Maiorano et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: